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An important goal for personalized treatment is predicting response to a particular
therapeutic. A drawback of biological treatment is immunogenicity and the development
of antibodies directed against the drug [anti-drug antibodies (ADA)], which are associated
with a poorer clinical outcome. Here we set out to identify a predictive biomarker that
discriminates rheumatoid arthritis (RA) patients who are more likely to develop ADA in
response to adalimumab, a human monoclonal antibody against tumor necrosis factor
(TNF)α. By taking advantage of an immune-phenotyping platform, LEGENDScreenTM, we
measured the expression of 332 cell surface markers on B and T cells in a cross-sectional
adalimumab-treated RA patient cohort with a defined ADA response. The analysis
revealed seven differentially expressed markers (DEMs) between the ADA+ and ADA−
patients. Validation of the DEMs in an independent prospective European cohort of
adalimumab treated RA patients, revealed a significant and consistent reduced frequency
of signal regulatory protein (SIRP)α/β-expressing memory B cells in ADA+ vs. ADA− RA
patients. We also assessed the predictive value of SIRPα/β expression in a longitudinal
RA cohort prior to the initiation of adalimumab treatment. We show that a frequency of
<9.4% of SIRPα/β-expressing memory B cells predicts patients that will develop ADA,
and consequentially fail to respond to treatment, with a receiver operating characteristic
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(ROC) area under the curve (AUC) score of 0.92. Thus, measuring the frequency of
SIRPα/β-expressing memory B cells in patients prior to adalimumab treatment may be
clinically useful to identify a subgroup of active RA subjects who are going to develop an
ADA response and not gain substantial clinical benefit from this treatment.
Keywords: B cells, rheumatoid arthritis, anti-drug antibodies, immunogenicity, SIRP, anti-TNF, adalimumab,
memory B cells
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease
that manifests as pain, swelling and stiffness of the joints
(1), with a 0.5–1% prevalence in the adult population (2).
Loss of tolerance drives disease onset and the associated
excessive inflammation can lead to destruction of cartilage
and bone erosion (1) as well as to systemic complications
including cardiovascular disorders, if left untreated (3). Over
the last few years the introduction of several biological drugs
has significantly improved the treatment of RA, particularly
for those patients that fail to control disease with the
use of conventional disease modifying anti-rheumatic drugs
(cDMARDs). Drugs neutralizing pro-inflammatory cytokines
including TNFα (adalimumab, infliximab, and etanercept) and
IL-6 (tocilizumab) as well as depleting B cells (rituximab), and
blocking T cell function (abatacept), are successfully used in the
treatment of RA (4).
A significant percentage of patients with RA receiving
biologics will mount an immune response against the drug
(immunogenicity), leading to the production of anti-drug
antibodies (ADA), often within the first 6 months of therapy (5).
This is associated with lower blood drug levels, unresponsiveness
to the drug, and a worse clinical outcome (6). Multiple clinical
studies have shown that the incidence of ADA differs depending
on the biological therapy administered. Immunogenicity occurs
in around 33% of adalimumab- and 63% of infliximab-treated
RA patients. A lower occurrence is reported after rituximab
or tocilizumab treatment with 11% and <8% of RA patients,
respectively, developing ADA (7–15). Circulating ADAs can form
immune complexes that increase the clearance of the drug. The
majority of ADAs against adalimumab have neutralizing capacity
and prevent the drug from interacting with its target (16). Of
interest, lower drug levels combined with the presence of ADA
at 3 months after treatment initiation, predicted lack of response
to adalimumab at 12 months (17). Since not all patients treated
with biological therapies develop ADA, the ability to identify
a biomarker/s to predict immunogenicity would considerably
improve the clinical management of RA.
B cells play a prominent role in RA pathogenesis
via the production of rheumatoid factor (RF) and anti-
cyclic-citrullinated peptide (anti-CCP) autoantibodies, in
addition to antibody-independent roles (18). B cells in the
periphery can be defined according to stages of maturation:
immature CD24hiCD38hi; memory CD24hiCD38lo; and mature
CD24intCD38intB cells. Numerical and functional alterations in
B cell subsets have been consistently reported in patients with RA
(18). Of interest IgD+CD27+memory B cells are enriched in the
synovium, compared to the peripheral blood, suggesting that the
migration of pathogenic memory B cells into inflamed synovium
may contribute to disease progression (19). Furthermore, RA
patients with active disease have been reported to have a reduced
frequency of regulatory B cells, which also exhibit functional
impairment (20).
Adalimumab is a fully human monoclonal antibody against
TNFα, which is often used as a first line biological therapy
for patients, who have failed to respond to treatment with
cDMARDs (21). We investigated cell surface markers associated
with the development of ADA in RA patients treated with
adalimumab using a high-throughput flow cytometry technology
(LEGENDScreenTM) combined with a systematic analysis
framework (SAF). Firstly, an immune-module composed of 7
differentially expressed markers (DEMs) discriminating ADA+
vs. ADA− RA patients, was identified in B cell subsets in a
cross-sectional cohort of adalimumab-treated RA patients
(UK-resident). Validation of the immune-module in an
independent prospective European cohort, analyzed 12 months
after adalimumab initiation, shows that the frequency of
SIRPα/β+memory B cells was significantly lower (<9.4%)
in ADA+ compared to ADA− RA patients. Moreover, we
show that this low frequency of SIRPα/β+memory B cells
prior to adalimumab treatment (<9.4%) is able to predict the
development of ADA in the same prospective European cohort
of RA patients. Thus, we propose that enumeration of memory B
cells expressing SIRPα/β prior to initiation of adalimumab could
prevent unnecessary treatment of patients that are unlikely to
respond to this therapy due to development of ADA.
MATERIALS AND METHODS
Study Design
A UK cross-sectional cohort of 20 adalimumab treated RA
patients and a European prospective cohort of 37 RA patients
switching to adalimumab treatment were recruited for this study
as part of the ABIRISK consortium (Anti-Biopharmaceutical
Immunization: prediction and analysis of clinical relevance
to minimize the RISK; www.abirisk.eu/). PBMCs and serum
samples were obtained and clinical information recorded for
time of visit. Peripheral blood was obtained from patients
attending the Rheumatology clinic at University College London
Hospital, London or at other ABIRISK centers in the France,
Netherlands and Italy. All patients matched the definition of
RA, as outlined in the ACR-EULAR classification (revised
2010, 1992 ACR original). We collected detailed clinical and
laboratory information corresponding to day of sampling, from
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clinical records where available including: DAS28 score, C-
reactive protein (CRP), rheumatoid factor (RF), erythrocyte
sedimentation rate (ESR), and anti-cyclic citrullinated peptide
antibody (anti-CCP), smoking status, gender, age, and body
mass index (BMI). We excluded sero-negative (RF and CCP
negative) patients, to reduce the risk of inclusion of patients
with spondyloarthropathy, which can sometimes be classified
within groups of seronegative RA patients. For the cross-
sectional study peripheral blood was taken at a single time
point from patients who were currently undergoing or had
previously been on adalimumab treatment. Forty-five milliliter
(35ml in France) of blood was collected in Heparin/Sodium
Vacutainer blood collection tubes for PBMC isolation (BD) and
a further 5ml serum sample is obtained in serum Vacutainer
SST tubes (BD). Patients with RA that were about to start
adalimumab treatment, having previously been treated with
either a different biological therapy or with cDMARDs, were
recruited to the prospective study. These patients were followed
longitudinally with collection of serum and PBMC samples
at baseline prior to starting adalimumab, and subsequently
at 1 and 12 months post commencement of treatment. To
minimize batch effect, PMBCs and serum were frozen at each
visit to allow simultaneous assessments to be performed for a
given individual. PBMCs were isolated using density gradient
centrifugation with Ficoll-Paque Plus (GEHealthcare) and frozen
at −80◦C in autologous plasma with 10% DMSO, and stored in
liquid nitrogen. Serum tubes were centrifuged to separate cellular
material from the serum and serum aliquots frozen and stored at
−80◦C. Ethical approval was obtained from the ethics committee
of; University College London Hospitals Health Service Trust
(14/LO/0506 and 14/SC/1200); CPP, Ile de France VII (13-048),
Academic Medical Centre, Amsterdam (METC 2013_304), and
Azienda Ospedaliero Univeritaria Careggi (2012/0035P82), and
all patients provided written informed consent.
Anti-drug Antibodies Measurements
Adalimumab ADA were measured using MSD GOLD 96-well
Streptavidin SECTORPlates (L15SA) and aMeso Scale Discovery
(MSD) MESO R© QuickPlex SQ 120 Instrument. The MSD
technology is based on electrochemiluminescence in a bridging
format. Adalimumab (Humira R©, Abbvie) was independently
labeled with either EZ-Link R© Sulfo-NHS-LC-Biotin (Thermo
scientific 21327) or MSD SULFO-TAG NHS-Ester (Meso Scale
Discovery, R91AO) according to the supplier’s instructions.
Plasma samples diluted at 1/10 (Minimum required dilution)
from patients were incubated overnight with biotin-labeled
adalimumab and then transferred on GOLD 96-well Streptavidin
SECTOR Plates (L15SA) blocked prior with 150 µl of casein in
PBS. The plate was then read on a MSD Sector Imager. The
negative control was composed of a pool of plasma from 10
negative healthy donors supplied by the French Blood Bank
(EFS, Rungis, France). The positive control was a pool of
four monoclonal anti-Adalimumab antibodies produced and
purified from a human B cell hybridoma by the Immune
Regulation Laboratory Institute for Research in Biomedicine
(IRB, Bellinzona) in the frame of the ABIRISK program. The
sensitivity of the assay was determined by testing eight serial
dilutions of the positive control spanning the cut point in
three independent assays. The sensitivity was 18 ng/ml for anti-
Adalimumab.
LEGENDScreenTM Immune Phenotyping
and Multi-Color Flow Cytometry
PBMCs were phenotyped using LEGENDScreenTM kits, as per
the manufacturers instructions. Data was collected on the BD
Verse flow cytometer and analyzed using FlowJo 8.7 software
(TreeStar).
For multi-color flow cytometry samples were stained with
live/dead fixable blue (Invitrogen), for 20min at RT and
antibodies for flow cytometry, for 30min at 4◦C as follows;
CD19 BV785 (HIB19), CD24 PECy7 (ML5) (BD), CD38 BV605
(HIT2, BV605), to define B cells and subsets, and combinations
of the following; SIRPα/β APC (SE5A5), CD324 APC-Fire750
(67A4), CD1c BV421 (L161), CD127 BV510 (AO19D5), CD1a
PE-Dazzle594 (HI149), CD167a PE (S1D6), CD138 APC (DL-
101) (all BioLegend unless stated otherwise). Appropriate FMO
controls were used, and samples were fixed before acquiring on
the flow cytometer. Data was collected on the BD LSR2 flow
cytometer (BD), and analyzed using FlowJo version 8.7 or 10.5.
Statistical Analysis
Statistical analyses were performed using Prism version 6
(Graphpad) and JMP (SAS) version 12. P < 0.05 were
considered as significant. Heatmaps were generated using
Multiple Experiment Viewer_4_8 (MeV_4_8) (TM4). DEMs
were determined using a two-tailed t-test or one-way ANOVA
where appropriate. Fold change was determined by calculating
the difference between groups as a ratio. Graphs show individual
data points, with mean and ±SEM. Outliers were removed
in the validation analysis using the ROUT method (Robust
regression and Outlier removal) in Prism (Q = 1%), where
stated. Principle component analysis (PCA) was performed
using JMP. Receiver operating characteristic (ROC) curves
were generated and area under the curve (AUC) calculated
in JMP.
RESULTS
LEGENDScreenTM Analysis Identifies an
Immune-Module Associated With ADA in
RA Patients Treated With Adalimumab
To identify biomarker/s associated with ADA response to
adalimumab we examined the surface immune-signature of
PMBCs isolated from 10 ADA− to 10 ADA+ RA patients
treated with adalimumab for a minimum of 12 months (Table 1).
PBMCs were stained with fluorescently-conjugated antibodies
identifying CD4+T cells, CD19+B cells, immature, mature, and
memory B cell subsets in addition to the 332 cell surface
markers included in the LEGENDScreenTM panel (Figure S1).
LEGENDScreenTM inter- and intra-assay reproducibility was
validated in an independent study (22). The expression-pattern
of surface markers on PBMCs appeared to be distinct between
ADA− and ADA+ RA patients (Figure 1A). The variation in
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TABLE 1 | Patient demographic and disease characteristics for LEGENDScreenTM discovery cohort (UK based).
Healthy Controls RA (adalimumab
ADA−)
RA (adalimumab
ADA+)
DMARDs treated RA
(biologic naïve)
n 18 10 10 10
Sex, female n (%) 15 (79) 7 (70) 9 (90) 9 (90)
Age (years), mean (SD) 35.2 (10.7) 62.4 (14.8) 53.4 (10.5) 45.6 (13.5)
DAS28 (SD) – 3.05 (1.06) 3.63 (1.69) 3.95 (1.76)
Seropositive (RF+/CCP+) (%) – 100 90 100
CRP mg/l (SD) – 14.07 (21.54) 5.64 (6.20) 6.78 (4.75)
CURRENT TREATMENT
DMARDs only (n) – 3* 1* 10
Adalimumab (n) – 5 8 –
Etanercept (n) – 1* – –
Tocliziumab (n) – 1* 1* –
CONCOMITANT DMARD TREATMENT
MTX use, n (%) – 7 5 5
Average MTX dose, mg/week, mean (SD) – 15.7 (3.6) 18 (51.1) 19 (2.0)
Prednisolone use, n (%) – 1 2 2
Hydroxychloroquine use, n (%) – 1 2 6
Sulfasalazine use, n (%) – 1 1 6
In the discovery cohort there are no statistical differences between ADA+ and ADA− RA patient groups (t-test, p < 0.05 was considered as significant), nor between ADA+ and ADA−
and DMARDs treated (ANOVA), expect for age between ADA− and DMARDs. *At point of sampling patients receiving a non-adalimumab treatment as indicated (Current Treatment) but
have previously been treated with adalimumab and tested for ADA against adalimumab. Values in the table represent mean ± standard deviation (SD), or number of patients (n) with
proportion of total (%) where indicated. Adalimumab dose 40mg every 2 weeks, tocilizumab dose 4 mg/kg every 4 weeks, etanercept does 25mg twice a week.
marker expression is also present following analysis of CD19+B
cells and CD4+T cells (Figure 1B), with a greater difference
observed in CD19+B cells than in CD4+T cells. As many of the
markers assessed by the LEGENDScreenTM platform were either
not expressed or were expressed at a very low level, to increase the
statistical power of future analyses, markers with<5% expression
on all samples tested were excluded from this study. Inclusion
of this criteria resulted in the removal of 74 B and 134 T cell
markers. Expression of the remaining markers was compared
between ADA+ and ADA− RA patients using multiple t-test
analysis. CD19+B cells showed highest number of DEMs (ADA−
vs. ADA+) (n = 22) compared to CD4+T cells (n = 11) (p <
0.05, multiple t-test) (Figure 1C). These results together with the
numerical and functional imbalance in CD19+B cells associated
with the pathogenesis of RA (18–20), prompted us to focus on
DEMs expressed by B cell subsets. Respectively, four, seven, and
19 DEMs were identified on mature, immature, and memory
B cells between ADA+ and ADA− RA patients (Figure 1D,
Table S1). Of note, all these DEMs are down-regulated in ADA+
RA patients.
Next, a systematic framework analysis (SFA) was used to
distinguish between DEMs associated with the presence of
ADA as opposed to disease severity and/or the effect of
adalimumab therapy (Figure S2). DEMs expressed on memory
B cells that correlated significantly with Disease Activity Score-
28 (DAS28) (n = 1) (Pearson correlation) were excluded from
our study, as these were considered to be due to RA-related
inflammation (Table S2). None of theDEMs identified onmature
and immature B cells correlated with DAS28. To account for
treatment effect, we compared the expression of the DEMs
in ADA−, ADA+, and cDMARD treated RA patients (RA-
D). Using one-way ANOVA analysis, we excluded DEMs that
were significantly different between ADA− and RA-D, but not
between ADA+ and RA-D, as these were considered to be
treatment related (Figure S3). Furthermore, we removed any
DEMs that no longer showed significance following ANOVA
analysis between ADA− and ADA+ samples. The application of
the SFA, followed by the application of an unbiased principal
component analysis (PCA), demonstrates that 7 remaining
DEMs, specifically CD167a and CD1c expressed on mature; IL-
7Rα, CD138, and CD324 on immature and SIRPα/β and CD1a
on memory B cells (expression shown in heatmap; Figure 2A)
have sufficient statistical power to discriminate between ADA+
and ADA− RA patients (Figure 2B); henceforth defined as the
“module.”
A Frequency of <9.4% of SIRPα/β+Memory
B Cells Constitutes a Risk Factor for ADA
Development
While previous studies have shown some molecular association
with the development of ADA in RA patients (23, 24), currently
there are no clinically accepted predictive biomarkers for ADA
development in anti-TNFα treatment. We validated the B cell
subset ADA-associated “module” in an independent prospective
European RA cohort (n = 37) (map of recruitment is shown
in Figure 3A), which was designed to assess immunogenicity
development following initiation of adalimumab treatment
(none of the patients included in this study had been previously
treated with adalimumab) (Table 2). Purified PBMCs and
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FIGURE 1 | LEGENDScreenTM analysis of adalimumab treated RA patients (cross-sectional cohort) identifies differences between ADA+ and ADA− individuals.
PBMCs from patients treated with adalimumab defined as ADA+ (n = 10) or ADA− (n = 10) were stained with LEGENDScreenTM for 332 cell surface markers, in
addition to antibodies against CD19, CD4 and CD24 and CD38. Heatmaps showing average frequency expression of each LEGENDScreenTM marker for each
sample group (ADA+ and ADA−) for PBMCs (A), and CD4+T cells and CD19+B cells (B). Markers are ranked according to expression in ADA− patients. Volcano
plot showing fold-change of frequency expression between patient groups (ADA−/ADA+) (Log2) and p-value (t-test) (Log10), no markers passed the Holm-Sidak
post-hoc test. Blue circle: significantly down-regulated markers; red circle significantly up-regulated markers, in ADA− vs. ADA+; (C) for CD4+T cells and CD19+B
cells, and (D) mature (CD24intCD38int), immature (CD24hiCD38hi), and memory (CD24hiCD38lo) B cells.
serum were collected at three time points: baseline prior
to commencement of treatment, 1 month and 12 months
after treatment initiation (Figure 3B), and ADA was measured
at each time point. Out of the 37 patients recruited, 5
seronegative (RF and CCP negative) and 2 of unknown
serological status were excluded from this study, to reduce
the risk of inclusion of patients with spondyloarthropathy
(Figure S4). A further 6 patients, which tested positive at baseline
(n = 5) or had transient ADA expression (n = 1) were
excluded.
Month 12 PBMCs from the prospective cohort were stained
for CD19, CD24, CD38, and the 7 DEMs as shown in Figure 2A.
Analysis showed that the frequency of SIRPα/β+memory B cells
was consistently reduced in ADA+ compared to ADA− RA
patients at the 1-year follow-up [t-test following removal of
outliers (ROUT Q = 1%) (25)]. None of the other module
markers were confirmed in this analysis (Figures 3C–E). To test
the ability of SIRPα/β+memory B cells to distinguish patients as
ADA+ or ADA− we generated a receiver operating characteristic
(ROC) curve, plotting sensitivity against specificity for different
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FIGURE 2 | LEGENDScreenTM analysis of adalimumab treated RA patients (cross-sectional cohort) identifies an immune-module associated with ADA.
LEGENDScreenTM analysis as Figure 1. (A) Heatmap showing mean frequency of differentially expressed markers (DEMs) (p-value defined in Table S1), between
patient groups on B cell subsets, following exclusion of markers associated with DAS28 and “treatment effect” (see Figure S2 for details). (B) PCA of frequency of
expression of the DEMs on the 20 adalimumab treated RA patients (ADA− black circles, ADA+ red squares) with contribution of each marker to the principal
components denoted by length and direction of the corresponding red arrow.
SIRPα/β values observed in our validation cohort at month 12
(Figure 3F). An area under the curve (AUC) value of 0.92 was
calculated, indicating that the frequency of SIRPα/β+memory
B cells is highly accurate at defining ADA positivity. A cut-off
value of 9.4% SIRPα/β+memory B cells was determined using
the calculation of sensitivity-(1-specificity), with individuals
expressing <9.4% deemed to be ADA+.
To further confirm that changes in SIRPα/β+memory B cell
frequencies were associated with ADA and not to any of the
other clinical or demographic parameters implicated in RA
(DAS28, CRP, ESR, age, BMI, ADA titer), a correlation analysis
of these variables was performed. None of the parameters
analyzed correlated significantly with the percentage of
SIRPα/β+memory B cells (Figure S5A). Furthermore, there were
no significant differences in the percentage of SIRPα/β+memory
B cells between patients stratified according to concomitant
treatment with methotrexate (MTX), gender or smoking status
(Figures S5B–D).
Of interest, the development of ADA in the prospective
cohort was associated with non-response or partial response
to adalimumab, according to the EULAR classification (67%)
(Figure 3G). The frequency of SIRPα/β+memory B cells
was significantly decreased in non-responders compared to
responder patients (Figure 3H). However, patient response to
treatment was independent from the quantities of ADA in
circulation, since ADA titer did not correlate with DAS28
(Figure S5E). Furthermore, the frequency of SIRPα/β+memory
B cells does not predict response to treatment in patients
treated with cDMARDs only, suggesting that frequency of
SIRPα/β+memory B cells is specific to ADA associated failure
of treatment (Figure S6). We therefore hypothesize that the
presence of <9.4% SIRPα/β+memory B cells in RA patients
prior to initiation of adalimumab treatment could be used as
biomarker to predict ADA development in these patients.
Frequency of SIRPα/β+Memory B Cells as
a Predictor of ADA
We envisaged two possible scenarios for the change in the
frequency of SIRPα/β+memory B cells: (i) all patients prior
to adalimumab treatment express a similar frequency of
SIRPα/β+memory B cells, and the frequency is down regulated
concomitantly to the development of ADA; (ii) patients that
will go on to develop ADA have fewer SIRPα/β+memory B
cells at baseline compared to the ADA− patients. Using the
cut-off value determined by ROC-curve analysis, described in
Figure 3F, 9 out of 20 patients assessed at baseline showed<9.4%
of SIRPα/β+memory B cells in circulation. Strikingly, 73% of
patients with SIRPα/β+memory B cell frequencies below the
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FIGURE 3 | Reduced frequency of SIRPα/β+ memory B cells is validated in ADA+ adalimumab treated RA patients. PBMCs and serum samples were collected
longitudinally (baseline, month 1 and 12 following start of treatment), from RA patients starting adalimumab treatment across Europe. For each visit ADA level was
measured by Meso Scale Discovery (MSD) technology. Month 12 PBMCs were stained for flow cytometry, for the module (7 markers), and the frequencies of cells
(Continued)
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FIGURE 3 | expressing the markers analyzed (n = 12 ADA−, n = 12 ADA+). Outliers removed using robust regression and outlier removal [ROUT (Q = 1%)]. (A)
Location of recruitment sites, and number of patients recruited following exclusions (Figure S4). (B) Timeline of sample collection. Frequency of expression of DEMs
on (C) mature, (D) memory and (E) immature B cells from the prospective cohort; scatter plots showing mean ±SEM. T-test analysis, **p ≤ 0.01. (F) Receiver
operating characteristic (ROC) curve for %SIRPα/β+memory B cells, AUC reported in figure. (G) Dot plot representing proportion of ADA− and ADA+ patients that are
responders (black) or non-responders (purple); each circle represents one prospective patient. (H) Scatter plot with mean and ±SEM of %SIRPα/β+memory B cells
for non-responder (NR) and responder (R) patients to adalimumab according to EULAR classification, red squares represent ADA+ patients and black circles ADA−
patients. T-test analysis, *p ≤ 0.05.
TABLE 2 | Patient demographic and disease characteristics for independent
prospective validation cohort (UK, France, Italy, Netherlands).
Healthy
Controls
RA (adalimumab
ADA−)
RA (adalimumab
ADA+)
n 31 12 12
Sex, female n (%) 24 (68) 8 (67) 10 (83)
Age (years), mean (SD) 27 (10.7) 59 (15.7) 45 (12.6)
DAS28 (SD) – 2.45 (1.2) 3.49 (1.2)
Seropositive (RF+/CCP+)
n (%)
– 12 (100) 12 (100)
CRP mg/l (SD) – 7.5 (11.6) 9.2 (9.1)
LOCATION
UK 1 1
France 6 3
Italy 1 1
Netherlands 4 7
CONCOMITANT DMARD TREATMENT
MTX use, n (%) 10 (83.3%) 8 (66.7%)
Average MTX dose,
mg/week, mean (SD)
18.25 (5.3) 15.63 (6.6)
Prednisolone use, n (%) 1 (8.3%) 3 (25%)
Prednisone use, n (%) 3 (25%) 3 (25%)
Hydroxychloroquine use,
n (%)
3 (25%) 0 (0%)
Leflunomide use, n (%) 0 (0%) 3 (25%)
Sulfasalazine use, n (%) 2 (17%) 0 (0%)
CRP and DAS28 are not statistically different; age is statistically different (p = 0.04)
between ADA+ and ADA− RA cohorts. Values in the table represent mean ± standard
deviation (SD), or number of patients (n) with proportion of total (%) where indicated.
Month 12 (M12). All patients received 40mg adalimumab every other week.
cut-off value became ADA+ after 12 months of adalimumab
therapy whilst 80% of patients with SIRPα/β+memory B cell
frequencies above the cut-off value remained ADA− (Figure 4A).
Representative expression of SIRPα/β on memory B cells in
ADA− vs. ADA+ RA patients is shown in Figure 4B. To
confirm the predictive value of reduced SIRPα/β+ memory
B cells frequency, baseline samples were separated according
to future development of ADA by month 12. Patients that
will develop ADA showed significantly lower frequencies of
SIRPα/β+memory B cells compared to patients that do not
develop ADA (p = 0.0002) (Figure 4C). Longitudinal analysis
revealed no changes in the frequency of SIRPα/β+ memory
B cells between visits in both ADA− and ADA+ patients
(Figures 4D,E). Furthermore, analysis of the month 1 visit
revealed that the majority (80%) of patients that have developed
ADA by month 12 already have detectable ADA by 1 month
following start of treatment (Figure 4E).
DISCUSSION
Biological therapies are routinely used to treat autoimmune
conditions such as RA and have significantly improved the
management of these diseases. Despite their success, some
patients develop immune reactions against these therapies, and
develop ADA, which often leads to treatment failure (10, 17, 26–
28). Different drugs possess different degrees of immunogenicity,
for example adalimumab, a whole mAb, is more immunogenic
than etanercept, a fusion protein that contains only the Fc
portion of an antibody (26, 29). While to a certain extent,
increasing drug dosage has been shown to alleviate the side effects
associated with the presence of ADA (30), there is a need to
be able to predict which individuals will develop ADA. Here
we aimed, using extensive immune-phenotyping, to identify a
predictive biomarker associated with ADA. By using a UK cross-
sectional cohort of adalimumab-treated RA patients, followed by
validation in a European prospective cohort, we have identified
that a reduced frequency of SIRPα/β+memory B cells prior to
adalimumab treatment, compared to ADA− RA patients, allows
the prediction ADA development in RA patients. In addition,
we show that the lower frequency of SIRPα/β+memory B cells,
remains relatively stable following treatment with adalimumab.
In general, one of the major pitfalls in this type of study is the lack
of reproducibility of a biomarker. This is often due to the absence
of validation in independent cohorts (31–33). We mitigated this
problem by validating our results in an independent cohort that
included patients of mixed ethnicity. It would be important to
investigate whether the presence of <9.4% of SIRPα/β+memory
B cells also predicts ADA formation in patients with other
autoimmune diseases treated with biologics [e.g., inflammatory
bowel disease (IBD) treated with adalimumab] or in RA patients
treated with other biologics (e.g., infliximab). This would allow
us to establish whether the development of ADA is a feature of
autoimmunity or is disease/treatment specific.
Studies looking at the efficacy of the biosimilar to the original
drug have shown that the biosimilars have comparable efficacy
(34). It has been demonstrated that in patients who have
developed ADA against infliximab, the ADA will cross-react with
the biosimilar, as shown for Remsima in IBD (35) and Inflectra
in RA (36). On this basis we would expect the frequency of
SIRPα/β+memory B cells to also be reduced in patients that lack
response to/have ADA against adalimumab biosimilars, however
this will be subject to future investigation.
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FIGURE 4 | Low %SIRPα/β+memory B cells predict ADA development in adalimumab treated RA patients. PBMCs from the cohort described in Figure 3 taken at
baseline, month 1 (M1) and 12 (M12) visits (n = 21), were stained with SIRPα/β-APC for flow cytometry (n = 11 ADA+ n = 10 ADA−). (A) RA patients prior to
commencing adalimumab (baseline, from prospective cohort) were stratified according to the frequency of SIRPα/β+memory B cells. Black circle and red square
correspond to individuals, respectively, that do not “ADA−” or do “ADA+” develop ADA, after unblinding. Dotted line is the threshold value from M12 ROC curve
analysis. (B) Representative flow cytometry plots showing %SIRPα/β+memory B cells in an “ADA−” and an “ADA+” individuals. (C) Scatter plot showing mean ±
SEM of %SIRPα/β+memory B cells of patients at baseline, sub-divided by ADA development by M12, t-test analysis, following a robust regression and outlier removal
[ROUT (Q = 1%)], identifying two outliers, ***p ≤ 0.0001. (D) Graph showing longitudinally the %SIRPα/β+memory B cells at baseline, M1 and M12 for ADA− patients
stratified as (C), dotted line as 4A, one-way ANOVA. (E) %SIRPα/β+memory B cells for ADA+ patients; red square shows positive ADA detection, black circle shows
negative ADA detection, at sampling.
It is tempting to propose that the measurement of the
frequency of SIRPα/β+memory B cells could also be used as a
surrogate marker for ADA in the clinic for patients already being
treated with adalimumab. This could be done in combination
with or as an alternative and more practical method to those
already existing (37). The ability to detect ADA could help
to inform clinicians as to when switching treatment is most
needed. Overall, the ability to detect ADA in patients already
on treatment would potentially deliver precision medicine to
this heterogeneous disease and increase the efficiency of clinical
decision-making.
There is currently no functional data showing the role of
SIRP in B cells. SIRPα has been shown to have a possible
role in auto-immunity having been found to be a risk loci in
individuals with Type 1 Diabetes (38), and Crohn’s patients have
increased SIRPα/β+CD11C+DCs in the mesenteric lymph nodes
and inflamed intestinal mucosa (39). SIRP alpha and beta are
members of the Signaling Inhibitory Receptor Protein (SIRP)
family, and are membrane expressed proteins. Predominantly
found onmyeloid cells, they act tomediate cell to cell interactions
by regulating the type and strength of the signal (40). The major
ligand for SIRPα is CD47, which is ubiquitously expressed and
has a role in apoptosis, proliferation, adhesion and migration
(41), while SIRPβ has no known ligand. It is interesting to note
that not all individuals with low frequency of SIRPα/β+memory
B cells develop ADA, suggesting the existence of specific
risk factors, genetic or environmental, that predisposes some
individuals to develop ADA.
In this study we have demonstrated the value of measuring
the frequency of SIRPα/β+memory B cells for the prediction
of RA patients at risk of developing ADA against adalimumab.
However, one limitation of our study is the sample sizes available
due to the low frequency of ADA+ patients. Therefore, several
outstanding questions remain unanswered and will need to
be addressed in a larger cohort of patients. For example, it
would be interesting to address whether SIRPα/β is also a
genetic risk loci associated with ADA development in patients
with RA, and whether the low frequency of SIRPα/β+memory
B cells in RA patients prior to adalimumab treatment is
exclusively a biomarker for ADA response or whether the
reduction of this population is also mechanistically implicated
in the development of an ADA response. In addition, it is
possible that age and other disease specific factors such as
previous and concomitant treatments, and disease duration,
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may also have an effect on ADA development. Of note,
our data showing that there is no significant difference
in the frequency of SIRPα/β+memory B cells between RA
patients that are responders vs. non-responders to cDMARD
treatment supports that the frequency of SIRPα/β+memory
B cells is related to an ADA-specific lack of response
(Figure S5).
In conclusion we have identified a predictive marker present
prior to adalimumab treatment that it is associated with the
development of antibodies against adalimumab in patients with
RA; specifically, a frequency of <9.4% of SIRPα/β+memory
B cells. To our knowledge this is the first extensive immune
phenotyping analysis of B cells in a longitudinal cohort of RA
patients treated with adalimumab. We envisage that this can be
used as part of a toolkit combining other biomarkers, and genetic
and other risk factors, that will allow for more personalized
treatment.
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